If I Could Buy Only 1 High-Yield Dividend Stock in October for Passive Income, This Would Be It

Clorox (NYSE: CLX) is undergoing a significant operational overhaul, including a major ERP system rollout, which is projected to cause a 5-9% organic sales decline and an 18-23% adjusted EPS drop in fiscal year 2026 due to transition costs and inventory adjustments. This strategic investment, following pandemic-era missteps and a cyberattack, has driven the stock price below pre-pandemic levels and pushed its dividend yield to a decade-high of 4.2%. Despite near-term headwinds and substantial transition costs, the company anticipates long-term efficiency gains and cost reductions, positioning it as a contrarian opportunity for patient investors expecting a recovery by fiscal 2027.

Analysis

Clorox (CLX) is undergoing a significant operational overhaul, centered on a new ERP system rollout, which is projected to severely impact its fiscal year 2026 performance. The company forecasts organic sales to decrease by 5-9% and adjusted EPS to decline by 18-23%, largely due to transition costs and pre-shipping inventory to retailers. This ERP implementation is expected to incur $570-580 million in total costs and an $0.85-$0.95 impact on adjusted EPS.

This strategic investment aims to modernize a decades-old system, improve internal operations, supply chain efficiency, and data management, positioning Clorox for long-term cost reductions and value creation. The move follows past operational challenges, including misjudged pandemic demand and a 2023 cyberattack that disrupted operations and eroded investor confidence. The current stock price is below pre-pandemic levels, reflecting these historical issues and the near-term headwinds.

Despite the near-term operational disruptions and weak guidance, Clorox's stock currently offers a 4.2% dividend yield, its highest in a decade, supported by 48 consecutive years of dividend increases. Management anticipates a recovery and return to growth by fiscal 2027, suggesting that the fiscal 2026 downturn is a temporary "transition year." This situation presents Clorox as a contrarian opportunity for patient investors willing to overlook short-term volatility for potential long-term operational improvements and dividend income.

Key Decisions for Investors

• Monitor Clorox's Q1 FY2026 earnings report on November 3rd for further details on ERP implementation progress and any adjustments to guidance.
• Evaluate the long-term investment thesis based on the company's ability to execute the ERP transition smoothly and demonstrate operational efficiencies leading to growth by FY2027.
• Consider Clorox as a potential contrarian play for patient, income-focused investors, given its high dividend yield and the expectation of a turnaround post-FY2026.
• Assess the broader consumer staples sector trends and inflationary pressures, as these macro factors could also influence Clorox's recovery trajectory.